VIR
Vir Biotechnology Inc

6,333
Loading...
Loading...
News
all
press releases
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
Zacks·1mo ago
News Placeholder
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·2mo ago
News Placeholder
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday...
Business Wire·7mo ago
News Placeholder
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2024, on...
Business Wire·7mo ago
News Placeholder
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
investing.com·8mo ago
News Placeholder
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer...
Yahoo! Finance: News·8mo ago
News Placeholder
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and...
Business Wire·8mo ago
News Placeholder
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday...
Business Wire·9mo ago

Latest VIR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.